Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005–2018

Masao Iwagami (), Ryosuke Kumazawa, Yoshihisa Miyamoto, Yuri Ito, Miho Ishimaru, Kojiro Morita, Shota Hamada, Nanako Tamiya and Hideo Yasunaga
Additional contact information
Masao Iwagami: University of Tsukuba
Ryosuke Kumazawa: The University of Tokyo
Yoshihisa Miyamoto: The University of Tokyo
Yuri Ito: Osaka Medical College
Miho Ishimaru: University of Tsukuba
Kojiro Morita: University of Tsukuba
Shota Hamada: Association for Health Economics Research and Social Insurance and Welfare
Nanako Tamiya: University of Tsukuba
Hideo Yasunaga: London School of Hygiene and Tropical Medicine

Drug Safety, 2021, vol. 44, issue 3, No 8, 371 pages

Abstract: Abstract Introduction In September 2019, ranitidine and nizatidine were suggested to contain N-nitrosodimethylamine, a carcinogenic substance. People have since been concerned about the potential impact of ranitidine/nizatidine use on the risk of cancer. Objective The objective of this study was to investigate the risk of cancer among people receiving ranitidine or nizatidine compared with other histamine 2 receptor antagonists (H2 blockers) [cimetidine, famotidine, roxatidine, and lafutidine]. Methods In the Japan Medical Data Center claims database (comprising people aged 730 DDDs. Conclusions We found no evidence that ranitidine/nizatidine is associated with an increased risk of cancer, although further studies with more accurate measurement of exposure, inclusion of older people, and longer follow-up may be needed.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-01024-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:3:d:10.1007_s40264-020-01024-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-01024-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().